PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 4 | 3 | A117-120
Article title

Everolimus – effectively reverses acquired resistance on endocrine therapy of patients with advanced breast cancer. A case report

Content
Title variants
Languages of publication
EN
Abstracts
EN
Breast cancer is the most common malignancy among women in Poland. Endocrine therapy is the first line of treatment in hormone-receptor-positive advanced breast cancer. Progression during endocrine therapy is unavoidable. Administration of mTOR inhibitor gives a chance of reversing the acquired resistance. This paper presents a case report of a patient with metastatic breast cancer successfully treated with everolimus added to endocrine therapy.
Discipline
Publisher
Journal
Year
Volume
4
Issue
3
Pages
A117-120
Physical description
References
  • Krzakowski M., Fijuth J., Herman K. et al.: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Tom I. Polska Unia Onkologii 2013.
  • Wojciechowska U., Didkowska J., Zatoński W.: Prognozy zachorowalności i umieralności na nowotwory złośliwe w Polsce do 2025 r. Krajowy Rejestr Nowotworów, Centrum Onkologii Instytutu im. M. Skłodowskiej-Curie.
  • Blamey R.W., Cataliotti L.: EUSOMA accreditation of breast units. Eur. J. Cancer 2006; 42: 13331-1337.
  • Wilcken N., Hornblucke J., Ghersi D.: Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst. Rev. 2003; (2): CD002747.
  • Wong M.H.F., Stockler M., Pavlakis N.: Bisphosphonates and other bone agents for breast cancer. Cochrane Library February 2012.
  • Van Poznak C.H., Temin S., Yee G.C. et al.: American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J. Clin. Oncol. 2011; 29(9): 1221-1227.
  • Cardoso F., Costa A., Norton L. et al.: 1st International consensus guidelines for advanced breast cancer (ABC 1). The Breast 2012; 21(3): 242-252.
  • Łacko A., Duchnowska R.: The place of exemestane in the treatment of advanced breast cancer in postmenopausal patients. Onkol. Prakt. Klin. 2012; 8(6): 246-251.
  • Wojtukiewicz M., Sierko E.: Leczenie ukierunkowane na cele molekularne w onkologii i hematoonkologii. Via Medica 2013.
  • Baselga J., Campone M., Piccart M. et al.: Everolimus in post-menopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012; 366: 520-529.
  • Amir E., Miller N., Geddie W. et al.: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 2012; 30: 587-592.
  • Simmonds C., Miller N.,Geddie W. et al.: Does confirmatory tumor biopsy alter the management of breast cancer with distant metastases? Ann. Oncol. 2009; 20: 1499-1504.
  • Cardoso F., Fallowfield L., Costa A. et al.; ESMO Guidelines Working Group: Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2011; 22(suppl. 6): 25-30
Document Type
report
Publication order reference
YADDA identifier
bwmeta1.element.psjd-e7024a1f-b633-49dd-b31c-b9c5cac84cc8
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.